ATE391186T1 - Gezielte verabreichung von kuenstlichen genen - Google Patents

Gezielte verabreichung von kuenstlichen genen

Info

Publication number
ATE391186T1
ATE391186T1 AT00957535T AT00957535T ATE391186T1 AT E391186 T1 ATE391186 T1 AT E391186T1 AT 00957535 T AT00957535 T AT 00957535T AT 00957535 T AT00957535 T AT 00957535T AT E391186 T1 ATE391186 T1 AT E391186T1
Authority
AT
Austria
Prior art keywords
targeted administration
artificial genes
artificial
targeted
gene delivery
Prior art date
Application number
AT00957535T
Other languages
English (en)
Inventor
Yanina Rozenberg
Viacheslav Medvedkin
W Anderson
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE391186T1 publication Critical patent/ATE391186T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00957535T 1999-08-19 2000-08-18 Gezielte verabreichung von kuenstlichen genen ATE391186T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/377,153 US20020064520A1 (en) 1999-08-19 1999-08-19 Targeted artificial gene delivery

Publications (1)

Publication Number Publication Date
ATE391186T1 true ATE391186T1 (de) 2008-04-15

Family

ID=23487987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957535T ATE391186T1 (de) 1999-08-19 2000-08-18 Gezielte verabreichung von kuenstlichen genen

Country Status (10)

Country Link
US (2) US20020064520A1 (de)
EP (1) EP1204761B1 (de)
JP (1) JP2003507348A (de)
CN (1) CN1237179C (de)
AT (1) ATE391186T1 (de)
AU (1) AU6913800A (de)
CA (1) CA2380517A1 (de)
DE (1) DE60038494D1 (de)
NZ (1) NZ517241A (de)
WO (1) WO2001012235A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875448B1 (en) * 1999-09-03 2005-04-05 Chugai Seiyaku Kabushiki Kaisha Method of intracellular sustained-release of drug and preparations
CA2404737C (en) * 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
WO2003040399A2 (en) * 2001-11-02 2003-05-15 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
EP1585560A4 (de) * 2002-07-26 2011-03-16 Mirus Bio Corp Zuführung von molekülen und komplexen zu säugerzellen in vivo
WO2004072289A1 (ja) 2003-02-17 2004-08-26 Fuso Pharmaceutical Industries, Ltd. 新規ウイルスベクター
EP1559790A1 (de) * 2004-02-02 2005-08-03 International University Bremen Gmbh Vesikel zum Abtrennen von Substanzen aus flüssigen Medien
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
WO2008108776A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US8865188B2 (en) 2011-09-09 2014-10-21 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
US11246877B2 (en) * 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
JP2000509394A (ja) * 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体
WO1998044143A1 (en) * 1997-04-03 1998-10-08 Genzyme Corporation Polymer-modified viruses
JP2001523089A (ja) * 1997-04-10 2001-11-20 南カリフォルニア大学 細胞外マトリックス成分に結合する修飾ウイルス表面蛋白質
EP1093519A2 (de) * 1998-07-09 2001-04-25 The University Of Southern California Amphiphile peptide abgegleitet vom zytoplasmatischen ende der viralen hüllproteine

Also Published As

Publication number Publication date
JP2003507348A (ja) 2003-02-25
DE60038494D1 (de) 2008-05-15
EP1204761A2 (de) 2002-05-15
EP1204761B1 (de) 2008-04-02
WO2001012235A3 (en) 2001-05-25
CA2380517A1 (en) 2001-02-22
CN1237179C (zh) 2006-01-18
US20020064520A1 (en) 2002-05-30
NZ517241A (en) 2004-01-30
CN1420934A (zh) 2003-05-28
WO2001012235A2 (en) 2001-02-22
AU6913800A (en) 2001-03-13
US20080103108A1 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
ATE391186T1 (de) Gezielte verabreichung von kuenstlichen genen
EP1312679B8 (de) Rekombinante MVA Viren und deren Verwendung
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
FR2727689B1 (de)
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
ATE486614T1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE333284T1 (de) Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
WO1996041606A3 (en) Improved pharmaceutical compositions for gene therapy
WO1998039426A3 (en) Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
DE69830249D1 (de) Zielgerichtete liposomen zur verabreichung von genen
WO1998030709A3 (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
EP1149917A3 (de) Hepatitis B Vektoren für Gentherapie
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
RU2004104335A (ru) Биологически активные пептиды
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
NZ324157A (en) Conditionally replicating viral vectors and their use in treating HIV
WO2000006735A8 (en) Interferon alpha hybrids
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
WO2003061581A3 (en) Compositions and methods for regulating rna stability using polypyrimidine tract proteins
DE60013586D1 (de) Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties